K2 Principal Fund’s CERo Therapeutics CERO Stock Holding History

K2 Principal Fund’s Portfolio CERO Stock Details CERO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6	Closed	-$124K	–	319
2022 Q4	$124K	Buy	+6	New	+$122K	0.02%	163

Other funds holding CERO

Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Walleye Capital

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

K2 Principal Fund's CERO Position: Q1 2023 in Review

K2 Principal Fund sold out of CERo Therapeutics (CERO) in Q1 2023, closing a stake of 6 shares — an estimated $124K sold.

K2 Principal Fund first reported a position in CERO in Q4 2022 and held it in 1 quarter. The position peaked at $124K in Q4 2022. 15 funds tracked by Wall St. Rank hold CERO as of Q1 2023.

K2 Principal Fund reported no remaining CERo Therapeutics position as of Q1 2023 after selling out during the quarter.
K2 Principal Fund sold 6 CERo Therapeutics shares in Q1 2023, an estimated $124K.
K2 Principal Fund first reported a position in CERo Therapeutics in Q4 2022 and held it in 1 quarter.
K2 Principal Fund's CERo Therapeutics position peaked at $124K in Q4 2022.
15 funds tracked by Wall St. Rank held CERo Therapeutics as of Q1 2023.

Based on K2 Principal Fund's 13F filing for Q1 2023, filed 11 May 2023.